Abstract
In this manuscript, three-dimensional quantitative structure-activity relationship (3D-QSAR) studies using comparative molecule field analysis (CoMFA) techniques were applied to provide the structural information of Bcl-2 inhibitors. The CoMFA model obtained from the training set were all statistically significant with the cross-validated coefficients (q2) of 0.568 and conventional coefficients (r2) of 0.991. The contribution of steric field and the electrostatic field is 0.635 and 0.365, respectively. The 3D-QSAR model was furthermore validated by a test set of 6 molecules. The predicted correlation coefficient (r2 pred) on the test set is 0.582. Therefore, the 3D-QSAR models built may be used to exhibit the necessary ligand-based structural environment as well as to design novel Bcl-2 inhibitors with increasing activities.
Keywords: CoMFA, Bcl-2 protein, inhibitors, 3D-QSAR, Comparative Molecular Field Analysis, GPCRs, Sketch Molecule, Gasteiger-Huckel, Partial Least Square, r2pred, HMLP, electrostatic field, leave-one-out, Tripos force fieldCoMFA, Bcl-2 protein, inhibitors, 3D-QSAR, Comparative Molecular Field Analysis, GPCRs, Sketch Molecule, Gasteiger-Huckel, Partial Least Square, r2pred, HMLP, electrostatic field, leave-one-out, Tripos force field
Protein & Peptide Letters
Title: 3D-QSAR Study on a Series of Bcl-2 Protein Inhibitors Using Comparative Molecular Field Analysis
Volume: 18 Issue: 5
Author(s): Xuben Hou, Jintong Du, Hao Fang and Minyong Li
Affiliation:
Keywords: CoMFA, Bcl-2 protein, inhibitors, 3D-QSAR, Comparative Molecular Field Analysis, GPCRs, Sketch Molecule, Gasteiger-Huckel, Partial Least Square, r2pred, HMLP, electrostatic field, leave-one-out, Tripos force fieldCoMFA, Bcl-2 protein, inhibitors, 3D-QSAR, Comparative Molecular Field Analysis, GPCRs, Sketch Molecule, Gasteiger-Huckel, Partial Least Square, r2pred, HMLP, electrostatic field, leave-one-out, Tripos force field
Abstract: In this manuscript, three-dimensional quantitative structure-activity relationship (3D-QSAR) studies using comparative molecule field analysis (CoMFA) techniques were applied to provide the structural information of Bcl-2 inhibitors. The CoMFA model obtained from the training set were all statistically significant with the cross-validated coefficients (q2) of 0.568 and conventional coefficients (r2) of 0.991. The contribution of steric field and the electrostatic field is 0.635 and 0.365, respectively. The 3D-QSAR model was furthermore validated by a test set of 6 molecules. The predicted correlation coefficient (r2 pred) on the test set is 0.582. Therefore, the 3D-QSAR models built may be used to exhibit the necessary ligand-based structural environment as well as to design novel Bcl-2 inhibitors with increasing activities.
Export Options
About this article
Cite this article as:
Hou Xuben, Du Jintong, Fang Hao and Li Minyong, 3D-QSAR Study on a Series of Bcl-2 Protein Inhibitors Using Comparative Molecular Field Analysis, Protein & Peptide Letters 2011; 18 (5) . https://dx.doi.org/10.2174/092986611794927992
DOI https://dx.doi.org/10.2174/092986611794927992 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology Epivention: Epigenetic Based Cancer Chemoprevention
Epigenetic Diagnosis & Therapy (Discontinued) Meet Our Associate Editor
Current Biomarkers (Discontinued) Synthesis of New Benzofuran-Pyrazole Hybrids as Potential Antibiofilm Agents
Letters in Drug Design & Discovery Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Molecular Docking and Dynamic Simulation Studies of Terpenoids of I. wightii (Bentham) H. Hara against Acetylcholinesterase and Histone Deacetylase3 Receptors
Current Computer-Aided Drug Design Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Correlation between Antioxidant/Antimutagenic and Antiproliferative Activity of Some Phytochemicals
Anti-Cancer Agents in Medicinal Chemistry How Much is Enough? Modulation of Dose-Response Curve for Steroid Receptor-Regulated Gene Expression by Changing Concentrations of Transcription Factor
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: NADPH Oxidase-Derived ROS Signaling and Therapeutic Opportunities)
Current Pharmaceutical Design Thomsen-Friedenreich Disaccharide Immunogenicity
Current Cancer Drug Targets The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Current Pharmaceutical Design New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors
Current Medicinal Chemistry Editorial [Human Methylome Variation and the Rise of Epigenetic Epidemiology]
Current Pharmacogenomics and Personalized Medicine Ribonucleotide Reductase as One Important Target of [Tris(1,10- phenanthroline)lanthanum(III)] Trithiocyanate (KP772)
Current Cancer Drug Targets Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
Recent Patents on Anti-Cancer Drug Discovery Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics The Importance of Stereochemistry on the Actions of Vitamin D
Current Topics in Medicinal Chemistry